## Special Lecture 1

**Friday, June 24th, 2016 11:20~12:00**  
Venue 1 (1F Philharmonia Hall)

**Chair:** Mototsugu Kato  
(National Hospital Organization Hakodate Hospital)

### SL1

**Helicobacter pylori Therapy: The Paradigm Shift**  
David Yates Graham  
(Department of Medicine, Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX USA)

## Special Lecture 2

**Saturday, June 25th, 2016 11:20~12:00**  
Venue 1 (1F Philharmonia Hall)

**Chair:** Hidekazu Suzuki  
(Medical Education Center, Keio University School of Medicine)

### SL2

**Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China**  
Hao Zeng  
(Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military University and National Immune Products Engineering Technology Research, Beijing, China)

## Special Lecture 3

**Saturday, June 25th, 2016 13:05~14:05**  
Venue 3 (1F Conference room)

**Chair:** Jaw-town Lin  
(College of Medicine, Fu Jen Catholic University, Taiwan Dean)  
Kentaro Sugano  
(Jichi Medical University)

### SL3-1

**New Strategy of Helicobacter pylori Eradication Therapy in Taiwan**  
Ming-Shiang Wu  
(Division of Gastroenterology, College of Medicine, National Taiwan University, Taipei, Taiwan)

### SL3-2

**New strategies of H. pylori eradication treatment in China**  
Hong Lu  
(GI Division, Shanghai Jiao Tong University School of Medicine, Shanghai, China)

### SL3-3

**Antibiotic Resistances in Asia**  
Jyh-Ming Liou  
(Internal Medicine / Gastroenterology, National Taiwan University Hospital, Taipei, China)
Lecture by Chief Director
Friday, June 24th, 2016 10:40~11:20 Venue1 (1F Philharmonia Hall)

Chair: Yoshihiro Fukuda
(Kyowakai Medical corporation Second Kyoritsu Hospital)

The perspective and issues to be solved in Japanese Society of *Helicobacter* Research
Toshiro Sugiyama
(President of JSHR)

President Lecture
Saturday, June 25th, 2016 8:30~9:00 Venue1 (1F Philharmonia Hall)

Chair: Takeshi Matsuhisa
(Past-Nippon Medical School Tama Nagayama Hospital)

Epidemiological Studies: we should go to the survey by ourselves
Yoshio Yamaoka
(Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine
Department of Medicine-Gastroenterology, Baylor College of Medicine and Michael
E. DeBakey Veterans Affairs Medical Center)
Symposium1
Friday, June 24th, 2016  13:10~14:40  Venue2 (3FInternational Conference room)

Change of gastric mucosa after eradication

Chair: Takashi Kawai
(Endoscopy Center, Tokyo medical University Hospital)
Tomoari Kamada
(Kawasaki Medical School)

S1-1 Relationship between endoscopic atrophic classification and histological atrophy and intestinal metaplasia.
Masaaki Kodama
(Faculty of Welfare and Health Science, Oita University,
Department of Gastroenterology, Faculty of Medicine, Oita University)

S1-2 Gastric mucosa after Successful *Helicobacter pylori* Eradication Therapy
Yosuke Iriguchi
(Tokyo Metropolitan Cancer Detection Center)

S1-3 Endoscopic characteristics of early gastric cancers discovered after *Helicobacter pylori* eradication
Yuji Maehata
(Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University)

S1-4 Endoscopic features of gastric epithelial neoplasm after *H. pylori* eradication
Emiko Tanida
(Department of Gastroenterology, Machida municipal hospital)

S1-5 The characteristics of reddish depressed lesion after eradication and its accurate endoscopic diagnosis
Takahiro Kotachi
(Department of Gastroenterology and Metabolism, Hiroshima University)

S1-6 Evaluation of diagnosis in depressive gastric cancer after *H. pylori* eradication using mucosal structure.
Kyosuke Yanagisawa
(Endoscopy Center, Tokyo Medical University Hospital)

S1-7 Endoscopic and pathological findings after eradication of *Helicobacter pylori*
Junko Fujisaki
(Cancer Institute Hospital)

S1-8 What factors most influence to find out gastric cancer (GC) after eradication.
Yoshitaka Tokai
(Foundation for Detection of early gastric carcinoma.)
S1-9  Is Kyoto classification of gastritis useful to predict the recurrence of early gastric cancer?
Shinya Yamada
(Department of Gastroenterology and Hepatology, Japanese Red Cross Society Kyoto Daiichi Hospital)

Symposium2
Saturday, June 25th, 2016 9:00~11:15 Venue3 (1F Conference room)

Global Development of Helicobacter Researches
Chair: Yoshio Yamaoka
(Department of Environmental and Preventive Medicine, Oita University
Department of Medicine-Gastroenterology, Baylor College of Medicine and
Michael E. DeBakey Veterans Affairs Medical Center)
Takeshi Matsuhisa
(Past-Nippon Medical School Tama Nagayama Hospital)

S2-1  Helicobacter pylori Genome Project
Ichizo Kobayashi
(Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan)

S2-2  Preliminary Report
ASEAN Consensus 2016 on Helicobacter pylori Management
Varocha Mahachai
(Bangkok General Hospital, Bangkok, Thailand)

S2-3  H. pylori infection in Indonesia: why the prevalence of H. pylori was to low
Ari Fahrial Syam
(Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine University of Indonesia / Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia)

S2-4  Helicobacter pylori infection in Thailand and Myanmar
Ratha-korn Vilaichone
(Gastroenterology Unit, Department of Medicine, Thammasat University Hospital, Pathumthani, Thailand)

S2-5  H. pylori infection in Bhutan
Hoda Malaty
(Department of Medicine, Baylor College of Medicine, Houston, USA)

S2-6  Virulence factors and highly increasing antibiotic resistance of Helicobacter pylori in Vietnam
Ho Dang Quy Dung
(Department of Endoscopy, Cho-Ray Hospital, Ho Chi Minh, Vietnam)
S2-7  Prevalence of *Helicobacter pylori* infection and gastroduodenal diseases in minor ethnic groups in Vietnam
Vu Van Khien
(Department of Diagnostic Endoscopy, 108 Military Central Hospital, Hanoi, Vietnam)

S2-8  Characteristic of gastric cancer and *H. pylori* infection in Mongolia
Khasag Oyuntsetseg
(Gastroenterology and Hepatology unit, Department of Internal Medicine II, School of medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia)

S2-9  Human migration patterns in Asia revealed by *H. pylori*
Rumiko Suzuki
(Department of Environmental & Preventive Medicine, Oita University Faculty of Medicine, Yufu, Japan)
<table>
<thead>
<tr>
<th>Panel Discussion1</th>
<th>Friday, June 24th, 2016  8:40~10:40  Venue1 (1F Philharmonia Hall)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revised points of new guideline 2016</strong></td>
<td></td>
</tr>
</tbody>
</table>
| Chair : Naomi Uemura  
(Kohnodai Hospital, National Center for Global Health and Medicine)  
Mototsugu Kato  
(National Hospital Organization Hakodate Hospital) | |
| **PD1-1**  | The circumstances of guideline revision  |
| Mototsugu Kato  
(National Hospital Organization Hakodate Hospital) | |
| **PD1-2**  | Revised points of JSHR Guidelines: Indications for *H. pylori* eradication therapy  |
| Hidekazu Suzuki  
(Medical Education Center, Keio University School of Medicine) | |
| **PD1-3**  | Diagnosis in the new guidelines for the management of *Helicobacter pylori* infection in Japan.  |
| Tadashi Shimoyama  
(Gastroenterology, Hirosaki University Graduate School of Medicine) | |
| **PD1-4**  | Key points in the revision of the guideline for *H. pylori* eradication  |
| Takahisa Furuta  
(Center for Clinical Research, Hamamatsu University School of Medicine) | |
| **PD1-5**  | The new guideline: Strategy for gastric cancer prevention.  |
| Katsuhiko Mabe  
(Department of Gastroenterology, Department of Gastroenterology, National Hospital Organization Hakodate Hospital) | |
| **PD1-6**  | Special comments on revised guideline on management of *Helicobacter pylori* infection in Japan, 2016 issued by JSHR  |
| Toshiro Sugiyama  
(President of JSHR) | |
Program: Panel Discussion

Friday, June 24th, 2016  13:10~14:40  Venue1 (1F  Philharmonia Hall)

Challenges and approaches to extinguish gastric cancers from Japan
Chair:  Akiko Shiotani  
(Kawasaki Medical School)
Katsuhiro Mabe  
(National Hospital Organization Hakodate Hospital)

共催:  EA Pharma

<table>
<thead>
<tr>
<th>PD2-1</th>
<th>Effect of <em>Hp</em> eradication on gastric cancer risk markers; feasibility of serum TFF3 as cancer risk marker</th>
</tr>
</thead>
</table>
|         | Masami Tanaka  
(Toranomon hospital)                                                                                   |

<table>
<thead>
<tr>
<th>PD2-2</th>
<th>Screening endoscopy analyzed from characteristics of gastric cancer which were detected after eradication</th>
</tr>
</thead>
</table>
|         | Momoko Tsuda  
(Department of Gastroenterology and Hepatology,  Hokkaido University Graduate School of Medicine) |

<table>
<thead>
<tr>
<th>PD2-3</th>
<th>Incidence rate and risk factors of gastric cancer after successful <em>H. pylori</em> eradication</th>
</tr>
</thead>
</table>
|         | Atsushi Majima  
(Kyoto Prefectural University of Medicine)                                                           |

<table>
<thead>
<tr>
<th>PD2-4</th>
<th>Evaluation of a risk score system to predict gastric cancer following <em>H. pylori</em> eradication.</th>
</tr>
</thead>
</table>
|         | Masaaki Kodama  
(Faculty of Welfare and Health Science, Oita University)                                               |

<table>
<thead>
<tr>
<th>PD2-5</th>
<th>Positioning of gastric cancer risk screening in cancer control programs on the basis of experience in Yokosuka City</th>
</tr>
</thead>
</table>
|         | Yasuhiro Mizuno  
(Maru Clinic Yokosuka)                                                                                   |

<table>
<thead>
<tr>
<th>PD2-6</th>
<th>A new Barium x ray screening system including <em>Hp</em> diagnosis improved gastric cancer detection</th>
</tr>
</thead>
</table>
|         | Shiho Suzuki  
(Kakogawa West City Hospital)                                                                             |

<table>
<thead>
<tr>
<th>PD2-7</th>
<th>Suggested algorithms to screen gastric cancer and high risk subjects with diagnosis of background gastric mucosa</th>
</tr>
</thead>
</table>
|         | Shigemi Nakajima  
(JCHO Shiga Hospital)                                                                                   |

<table>
<thead>
<tr>
<th>PD2-8</th>
<th>Gastric cancer in negative test of anti-<em>H. pylori</em> antibody and pepsinogen test: A multicenter study</th>
</tr>
</thead>
</table>
|         | Mariko Kiso  
(Department of Gastroenterology and Metabolism, Hiroshima University Hospital)                       |
Comparison between the patients with chronic gastritis and the patients treated with ESD using Kyoto classification
Nobue Ueki
(Nippon Medical School, Department of Gastroenterology)

The relationship between COX-2 1195 genotype and high risk populations in H. pylori-infected gastritis.
Yasuhiro Kodaka
(Nippon Medical School, Division of Gastroenterology)

Annual changes of the eradication rate of first and second Helicobacter pylori eradication therapy
Hideki Mori
(Tokyo Helicobacter pylori study group)

Eradication for the youth to prevent gastric cancer
Chair: Shogo Kikuchi
(Masumi Okuda
(Department Public Health Aichi Medical University School of Medicine)
(Department of General Medicine and Community Health Science, Hyogo College of Medicine)

Test and treat of H. pylori for students: questionnaire to self-governing body and medical association
Masumi Okuda
(Department of General Medicine and Community Health Science, Hyogo College of Medicine)

Test & treat approach as the strategy for adolescents to eliminate gastric cancer.
Katsuhiro Mabe
(Department of Gastroenterology, National Hospital Organization Hakodate Hospital)

Side effects and safety of Metronidazole in Japanese middle school children
Chaohen Wang
(Department Public Health Aichi Medical University School of Medicine)

Clinical features of anti-H. pylori antibody positive junior high school students
Hitoshi Honma
(Department of Pediatrics, Shinshu University School of Medicine)

Antimicrobial resistance and eradication rate of Helicobacter pylori in children
Sawako Kato
(Department of Pediatrics, Shinshu University School of Medicine)
PD3-6  

*H. pylori* screening and eradication for junior high school students -Result for 3 years in Maniwa City-
Hidenori Kondo  
(Kondo Hospital)

PD3-7  

Examination and eradication for *Helicobacter pylori* infection in children in Akita prefecture  
Chika Kusano  
(Division of Gastroenterology and Hepatology Department of Medicine Nihon University School of Medicine, Yuri kumiai general hospital)

PD3-8  

Introduction of *H. pylori* screening into school medical examinations and clinical significance of serum pepsinogen  
Akihiro Ito  
(Department of gastroenterology, Shinshu University Hospital)

PD3-9  

The assessment of *Helicobacter pylori* eradication project for high school students in Kyoto  
Osamu Handa  
(Department of Molecular Gastroenterology and Hepatology)

---

**Panel Discussion**

Saturday, June 25th, 2016  9:00~11:00  Venue1 (1F Philharmonia Hall)

**Upcoming eradication methods including new drugs**

| Chair | Kazunari Murakami  
|       | (Department of gastroenterology Faculty of Medicine, Oita University.)  
|       | Kengo Tokunaga  
|       | (Third Department of Internal Medicine, Kyorin University School of Medicine)

PD4-1  

Current status of *Helicobacter pylori* eradication by electronic receipt analysis  
Momoko Tsuda  
(Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine)

PD4-2  

Current situation of eradication therapy using vonoprazan: Comparison with esomeprazole  
Takahide Tanaka  
(Matsuyama Red Cross Hospital Stomach and Intestines Center)

PD4-3  

Bonoplazan-based triple therapy will be standard for eradication therapy of *Helicobacter pylori* or not  
Ryuzo Murai  
(Onaka Clinic, Nonprofit Organization of Promoting *Helicobacter pylori* Check at Twenty year old)
PD4-4 Evaluation of eradication therapy for Helicobacter pylori with Vonoprazan Fumarate
Jun Nishikawa
(Yamaguchi University, Department of Laboratory Medicine)

PD4-5 An RCT comparing the first-line eradication rate using vonoprazan or PPI for H. pylori infectious gastritis
Masafumi Maruyama
(Department of Gastroenterology, Nagano Red Cross Hospital)

PD4-6 A novel potassium-competitive acid blocker rejuvenates CAM-containing 7-day triple therapy in H. pylori
Tetsuya Shinmura
(Aichi Medical University School of Medicine)

PD4-7 Is H. pylori eradication with vonoprazan superior to the therapy based on the antimicrobial sensitivity test?
Hiroki Tanabe
(International University of Health and Welfare Hospital)

PD4-8 Hp eradication therapy without penicillin—is vonoprazan useful?
Masayoshi Ito
(Tokyo Helicobacter study group)

PD4-9 Problems of accuracy of urea breath test after Vonoprazan-based eradication therapy
Takehiro Hayashi
(Yawata Medical Center)

PD4-10 Bifidobacterium bifidum YIT 10347 suppresses gut microbiota dysbiosis and severe diarrhea in H. pylori eradication
Toshifumi Ohkusa
(Department of Gastroenterology and Hepatology, The Jikei University Kashiwa Hospital)

PD4-11 Minimum inhibitory concentration changes of sitafloxacin after unsuccessful eradication
Hideki Mori
(Department of Internal Medicine, Division of Gastroenterology and Hepatology, School of Medicine, Keio University,
Department of Gastroenterology, National Hospital Organization Tokyo Medical Center)

PD4-12 A successful tailor-made eradication therapy for the third line
Shigemi Nakajima
(JCHO Shiga Hospital)

PD4-13 Eradication rates of H. pylori infection with sitfloxacin/Vonoprazan-based regimens
Takahisa Furuta
(Center for Clinical Research, Hamamatsu University School of Medicine)

PD4-14 Sitafloxacin based third-line therapy for H. pylori eradication. Vonoprazan is useful?
Kengo Tokunaga
(Tokyo HP study group)
Workshop 1
Friday, June 24th, 2016 14:50~16:20 Venue2 (3F International Conference room)

Revisiting *H. pylori*-related diseases (basic and clinical studies)
Chair: Hidekazu Suzuki
(Medical Education Center, Keio University School of Medicine)
Mitsushige Sugimoto
(Division of Digestive Endoscopy, Shiga University of Medical Science Hospital)
共催：Mylan EPD G.K., Taishotoyama Pharmaceutical Co., Ltd.

**WS1-1**
*H. pylori* induces methylation silencing of a mechano-sensitive ion channel, TRPV4 in human gastric epithelial cells
Hiroshi Mihara
(Department of Gastroenterology and Hematology)

**WS1-2**
*Helicobacter pylori* CagL and CagI variants related with type IV secretion system
Hirofumi Ogawa
(Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine)

**WS1-3**
*Helicobacter pylori* VacA toxin induces cell death by including accumulation of cytoplasmic Connexin 43
Kinnosuke Yahiro
(Department of Molecular Infectiology, Graduate School of Medicine, Chiba University)

**WS1-4**
New insight into the biological function of VacA in *H. pylori*-infected cells through RPTPalpha
Masayuki Nakano
(Department of Bacteriology, Institute of Tropical Medicine, Nagasaki University,
Department of International Health, Institute of Tropical Medicine, Nagasaki University)

**WS1-5**
Diversification of *alpAB* affects biofilm formation by *Helicobacter pylori*
Hideo Yonezawa
(Dept. of Infectious Diseases, Kyorin University School of Medicine)

**WS1-6**
IL-17C in human gastric mucosa with *Helicobacter pylori* infection
Shingo Tanaka
(Department of Medicine Gastroenterology and Hepatology, Baylor College of Medicine,
Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine)

**WS1-7**
TLR10 SNP affect susceptibility and pathological findings in *H. pylori* infection
Hiroyuki Nagashima
(Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine,
Rumoi City Hospital,
Sapporo Medical University Department of Medical Oncology and Hematology)
WS1-8  *Helicobacter pylori* eradication therapy for early-stage gastric diffuse large B-cell lymphomas.  
Shinichi Kawano  
(Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University)

WS1-9  Effect of eradication therapy for *H. pylori* to healing of artificial ulcer after endoscopic submucosal dissection  
Hiromitsu Ban  
(Shiga University of Medical Science, Division of Digestive Endoscopy)

WS1-10  The recurrence of *Helicobacter pylori* and recrudescence of ITP  
Tadayoshi Okimoto  
(Gastroenterology, Faculty of Medicine, Oita University)

WS1-11  *H. pylori* and symptoms in children with peptic ulcer disease  
Yoshiko Nakayama  
(Department of Pediatrics, Shinshu University School of Medicine)

WS1-12  Eradication of *Helicobacter pylori* for iron deficiency: report from Cochrane systematic review in authoring stage  
Kyoko Sakai  
(Department of Laboratory Medicine, Saiseikai Suita Hospital)

WS1-13  Association of estradiol and *Helicobacter pylori* infection with osteopenia in Japanese female.  
Daisuke Chinda  
(Hirosaki University, Graduate School of Medicine, Gastroenterology and Hematology)

---

**Workshop 2**  
Saturday, June 25th, 2016  14:40~16:10  Venue 1 (1F Philharmonia Hall)

**Other Helicobacters - microbiome and gastrointestinal diseases**

Chair: Takako Osaki  
(Department of Infectious Diseases, Kyorin University School of Medicine)  
Masahiko Nakamura  
(School of Pharmacy, Kitasato University)

WS2-1  *Helicobacter pylori* infection and gastric microbiota  
Takako Osaki  
(Dept of Infectious Diseases, Kyorin University School of Medicine)

WS2-2  2 cases of NPH-gastritis that are thought to have been independently sterilized by PPI.  
Toshihisa Tsukadaira  
(Iida Kenwakai Hospital)
WS2-3  Infected arterial aneurysm by *Helicobacter cinaedi*: a case report
Haruka Miyazaki
(Kobe Red Cross Hospital)

WS2-4  Analysis of diagnosis and clinical condition of *Helicobacter heilmannii*-like organisms infection in our hospital
Masahide Ebi
(Department of Gastroentelorogy, Aichi medical University School of Medicine)

WS2-5  Clinical problems of *Helicobacter heilmannii/suis*
Shinji Yoshii
(Department of gastroenterology, Sapporo Medical Center, NTT EC)

WS2-6  Non-*Helicobacter pylori*-Helicobacters in Japanese gastric patients negative for *H. pylori*, the second report
Anders Overby
(Kitasato University School of Pharmacy)

WS2-7  Prevalence of NHpH in Mongolian People Suffering from Upper Gastrointestinal Diseases
Masahiko Nakamura
(School of Pharmacy, Kitasato University)

---

**Workshop 3**
Saturday, June 25th, 2016  16:20~17:50  Venue1 (1F Philharmonia Hall)

**Reconsideration of infection diagnosis by serum antibody**
Chair: Takahisa Furuta
(Center for Clinical Research, Hamamatsu University School of Medicine)
  Masanori Ito
  (Department of gastroenterology and metabolism, Hiroshima University, Hiroshima, JAPAN)

WS3-1  Accuracy of diagnosing true *Helicobacter pylori*-negative cases by measuring serum anti-*Hp* antibody titer.
Tomoyuki Boda
(Department of Endoscopy, Hiroshima University Hospital)

WS3-2  Feasibility of cutoff value measured by supersensitive serum anti-*Hp* antibody titer in screening subjects
Takuji Gotoda
(Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine)

WS3-3  High value of *Helicobacter pylori* antibody less than cut-off value evaluated by the patients with gastric cancer
Shoko Ono
(Division of Endoscopy, Hokkaido University Hospital)
WS3-4  Utility of Gastric cancer risk screening and endoscopy as positive for more than 3.0U/ml and over of serum antibody
Mitsutaka Shuto
(Oita university faculty of medicine department of gastroenterology, Takada chuo Hospital)

WS3-5  Relation between false sero-negative results for H. pylori infection and gastric mucosal atrophy
Hitomi Ichikawa
(First Department of Medicine, Hamamatsu University School of Medicine)

WS3-6  Endoscopic mucosal atrophy and gastric cancer risk in the cases that show gray-zone H. pylori antibody titer
Takuji Yamasaki
/Foundation for detection of early gastric carcinoma

WS3-7  Clinicopathological studies of false negative serum H.pylori IgG antibody test in the patients.
Hiroshi Matsumoto
(Kawasaki Medical School)

WS3-8  Association with IgG subclass antibody to H. pylori and gastric cancer
Ko Miura
(Department of Gastroenterology and Hepatology, Okayama University Graduate)

WS3-9  Study of the lowering phenomenon in serum anti-Helicobacter pylori IgG antibody titers after eradication therapy
Nobuyuki Ohara
(Ohara family clinic)

WS3-10 Evaluation of new anti-H. pylori IgG antibodies for ABC screening
Chikara Iino
(Hirosaki Municipal Hospital, Department of Gastroenterology, Hirosaki University Graduate School of Medicine)
**BR1-1**  
*Geranylgeranylacetone selectively binds to Helicobacter pylori HSP70 and alters its coccoid morphology*

Shin-ichi Yokota  
(Department of Microbiology, Sapporo Medical University School of Medicine)

**BR1-2**  
*Histopathological characteristic of H. pylori infection in Asia*

Tomohisa Uchida  
(Department of Molecular Pathology, Oita University Faculty of Medicine)

**BR1-3**  
*The structure of genetic variation in Helicobacter pylori is a unique marker for human migrations*

Yoshan Moodley  
(Department of Zoology, University of Venda, Thohoyandou, South Africa)
## Poster Session 1

**Friday, June 24th, 2016  16:30~17:00  Poster Session (1F Convention Hall)**

### Bacteriology

**Chair:** Masayuki Nakano  
(Department of International Health, Institute of Tropical Medicine, Nagasaki University)

**P01-1**  
Regulation of adaptive phenotypes and genomic islands by a Type III RM system  
Hirokazu Yano  
(Grad.Sch.Front.Sci. Univ. Tokyo, IMSUT)

**P01-2**  
Identifications of, molecular bases of and functions of *Helicobacter pylori* ITAM-like GroELs associated with CagAs  
Momoyo Asahi  
(Center for Arts and Sciences Fukui Prefectural University)

**P01-3**  
Identifications of, molecular bases of and functions of *Helicobacter pylori* ITAM-like GroELs associated with CagAs  
Momoyo Asahi  
(Center for Arts and Sciences Fukui Prefectural University)

**P01-4**  
Intrinsic characteristics of Min proteins on the cell division of *Helicobacter pylori*  
Hiroaki Takeuchi  
(Clinical Laboratory Medicine, Kochi Medical School)

**P01-5**  
Survival and gene-expressions of *H. pylori* in co-culture with *A. castellanii.*  
Fuhito Hojo  
(Institute of Laboratory Animals, Graduate School of Medicine, Kyorin University)

---

## Poster Session 2

**Friday, June 24th, 2016  17:00~17:30  Poster Session (1F Convention Hall)**

### Clinical Aspects and so on

**Chair:** Norimasa Yoshida  
(Gastroenterology, Japanese Red Cross Society, Kyoto Daiichi Hospital)

**P02-1**  
Autophagy-related genes in Human *Helicobacter pylori* infection  
Shingo Tanaka  
(Department of Medicine Gastroenterology and Hepatology, Baylor College of Medicine,  
Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine)

**P02-2**  
Effects of vonoprazan on serum gastrin and pepsinogen in long-term PPI users.  
Yoshihisa Urita  
(Department of General Medicine and Emergency Care, Toho University School of Medicine)
P02-3  Investigation of FSSG and serum leptin level at pre and post *Helicobacter pylori* eradication
Mariko Kajiwara
(Department of Gastroenterology Kyoto First Red Cross Hospital)

P02-4  Investigation of epigastric pain syndrome with pancreatic dysfunction with endosonography.
Hiroshi Yamawaki
(Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School)

P02-5  Oxidative stress is related to pathogenesis of gastric cancer in *Helicobacter pylori* negative patients
Yoshiyasu Kono
(Department of Gastroenterology, Okayama University Hospital)

---

**Poster Session 3**
Friday, June 24th, 2016  16:30~17:00  Poster Session (1F Convention Hall)

<table>
<thead>
<tr>
<th>Gastric cancer and Pre-cancer lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair : Hiroyoshi Ota</td>
</tr>
<tr>
<td>(Biomedical Laboratory Sciences, Shinshu University)</td>
</tr>
</tbody>
</table>

P03-1  *Hp* infection in type A gastritis
Yasuhiko Maruyama
(Fujieda Municipal General Hospital)

P03-2  Age-specific histological changes in gastric mucosa after *Helicobacter pylori* eradication.
Hiroyuki Sakae
(Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences)

P03-3  A study on gastric cancer, *H.pylori* antibody negative and serum pepsinogen test negative
Masaru Mizutani
(Department of gastroenterology, Tokyo metropolitan cancer detection center)

P03-4  Features of *H. pylori* infection negative gastric cancer in our hospital and our affiliated hospital
Kazuhisa Okamoto
(Department of Gastroenterology Oita University)

P03-5  Xanthoma might be the predictive factor of synchronous and metachronous gastric cancers.
Narihiro Shibukawa
(Department of Gastroenterology, NTT West Osaka Hospital)
**Epidemiology and Transmission Routes**

Chair: Akinori Yanaka  
(Faculty of Medicine, Hitachi Medical Education and Research Center, University of Tsukuba)

- **P04-1**  
  **Influence of the sanitary environment at childhood on *Helicobacter pylori* infection**  
  Takunori Ueno  
  (Tsukuba Central Hospital)

- **P04-2**  
  **Changing prevalence of *Helicobacter pylori* infection at a tertiary center in Austria**  
  Yumiko Kamogawa  
  (Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Austria)

- **P04-3**  
  **Risk factors and prevalence of *Helicobacter pylori* in the suburbs of North Jakarta in Indonesia**  
  Yasuyuki Goto  
  (Nagoya Kyouritu Hospital)

- **P04-4**  
  **The relationship between urinary fucoidan level and *Helicobacter pylori* antibody titer in healthy volunteers.**  
  Kizuku Kadena  
  (South Product Co., LTD)

- **P04-5**  
  **A nested case-control study of *H. pylori* infection and risk of cardiovascular disease**  
  Yingsong Lin  
  (Department of Public Health, Aichi Medical University School of Medicine)

**Diagnosis and Examination of Infection-1**

Chair: Kazuhiko Inoue  
(Junpukai Health Care Center)

- **P05-1**  
  **Clinical trial of evaluation of new anti *Helicobacter pylori* antibody**  
  Hiroki Osumi  
  (Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research)
P05-2  Evaluation of the optimal cut-off values of serum *Helicobacter pylori* antibodies
Masayuki Inui
(Inui Clinic of Internal Medicine)

P05-3  Evaluation of a novel latex agglutination assay kit for the detection of anti-*H. pylori* IgG antibody
Takahisa Furuta
(Center for Clinical Research, Hamamatsu University School of Medicine)

P05-4  Study of the *Helicobacter* antibody by the difference of the measurement method.
Norio Kimura
(Department of Gastroenterology, Seocomedic Hospital)

P05-5  Comparison of *H. pylori* antibody between ELISA and LIA methods among strictly diagnosed *H. pylori* status
Nobuo Aoyama
(Aoyama Clinic, GI endoscopy and IBD)

---

**Poster Session 6**

Friday, June 24th, 2016 17:00~17:36  Poster Session (1F Convention Hall)

### Diagnosis and Examination of Infection-2

**Chair:** Shigemi Nakajima
(General Medicine, JCHO Shiga Hospital)

P06-1  False positive results increase when latex turbidimetric immunoassay rather than EIA is used to measure *Hp* antibody.
Masayoshi Ito
(Yotsuya medical cube)

P06-2  Efficacy of Serum *H. pylori* IgG antibody under medication of proton-pomp inhibitor
Eisuke Nakao
(Tane General Hospital)

P06-3  Evaluation of serum anti-*H. pylori* IgG antibody in patients with early gastric cancer who underwent ESD
Kazuto Takahashi
(Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui)

P06-4  Diagnosis of *Helicobacter pylori* infection status by serum levels of *Helicobacter pylori* antibody and pepsinogen.
Shinji Yoshii
(Department of Gastroenterology, SAPPORO MEDICAL CENTER, NTT EC)
P06-5  A proposal of development of a new serum *Helicobacter pylori* antibody kit to evaluate risk of gastric cancer  
Shogo Kikuchi  
(Department Public Health Aichi Medical University School of Medicine)

P06-6  Factors associated with serum *H. pylori* antibody titers  
Seiji Shiota  
(Oita University Faculty of Medicine, Department of General Medicine)

---

**Diagnosis and Examination of Infection-3**

Chair: Kenji Yokota  
(Graduate School of Health Science, Okayama University)

P07-1  Usefulness of serum pepsinogens for diagnosis of infection and judgement of eradication of *H. pylori* in children  
Shinichi Fujiwara  
(Sapporo Kosei General Hospital, Department of Pediatrics)

P07-2  Accuracy of stick-type kit and enzyme-linked immunosorbent assay for the detection of urinary *H. pylori* antibodies.  
Shiro Hayamizu  
(Hirosaki University, Graduate School of Medicine, Gastroenterology and Hematology)

P07-3  Assessments of the timing and the threshold of UBT for successful eradication of *H. pylori*  
Sohachi Nanjo  
(Department of Gastroenterology and Hepatology, Faculty of Medicine, University of Toyama)

P07-4  Effect of vonoprazan, a potassium-competitive acid blocker, on the $^{13}$C urea breath test in *H. pylori*-positive.  
Mayu Takimoto  
(Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine)

P07-5  gamma-glutamyltranspeptidase activated fluorescent can be useful of *H. pylori* infection diagnosis  
Taro Akashi  
(Department of Gastroenterology and Hepatology, Nagasaki University Hospital)
### Poster Session 8

**Friday, June 24th, 2016 16:30~16:54  Poster Session (1F Convention Hall)**

**Health Check**

*Chair: Yoshiko Nakayama*

(Department of Pediatrics, Shinshu University School of Medicine)

<table>
<thead>
<tr>
<th><strong>P08-1</strong></th>
<th>The results and future prospects of <em>H. pylori</em> antibody screening in Houki town, Tottori prefecture</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kazuo Yashima</td>
<td>(Division of Medicine and Clinical Science, Tottori university)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>P08-2</strong></th>
<th>Effectiveness of <em>H. pylori</em> test for new adults at a coming-of-age ceremony</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akira Horiuchi</td>
<td>(Showa Inan General Hospital Digestive Disease Center)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>P08-3</strong></th>
<th>Results of using the dedicated vehicle for trans nasal endoscopy in combination with gastric cancer risk screening.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Satoshi Ikeda</td>
<td>(Ikeda hospital)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>P08-4</strong></th>
<th><em>Helicobacter pylori</em> infection and colon polyps</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hiromi Nishiarai</td>
<td>(seikeikai chiba medical center medical examination center)</td>
</tr>
</tbody>
</table>

### Poster Session 9

**Friday, June 24th, 2016 16:30~17:00  Poster Session (1F Convention Hall)**

**Eradication Therapy-1**

*Chair: Shotaro Nakamura*

(Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University School of Medicine)

<table>
<thead>
<tr>
<th><strong>P09-1</strong></th>
<th>Efficacy of <em>H. pylori</em> eradication therapy under condition of rabeprazole qid for metronidazole-resistance strain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitsushige Sugimoto</td>
<td>(Division of Digestive Endoscopy, Shiga University of Medical Science Hospital)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>P09-2</strong></th>
<th>Comparison of Vonoprazan or Esomeprazole/CAM/MNZ First Line <em>H. pylori</em> Eradication for Penicillin Allergic patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soichiro Sue</td>
<td>(Yokohama city university gastroenterology)</td>
</tr>
</tbody>
</table>
P09-3 Comparative study of *Helicobacter pylori* eradication therapy using PPI and PCAB in our clinic
Rikako Sibata
(TANAKAGI CLINIC)

P09-4 Current status of the *Helicobacter pylori* eradication therapy at our hospital
Yuji Shimada
(Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital)

P09-5 The tendency of the outpatient clinic for *H. pylori* eradication in our hospital and the change of the eradication rate.
Junjiro Katsurada
(Sekishindo Hospital)

---

**Poster Session 10**
Friday, June 24th, 2016  17:00~17:30  Poster Session (1F Convention Hall)

**Eradiation Therapy-2**
Chair: Akira Horiuchi
(Digestive Disease Center, Showa Inan General Hospital)

P10-1 The results of eradication therapy for *Helicobacter pylori* infection using Vonoprazan
Hirotaka Ito
(Division of Gastroenterology, Osaki Citizen Hospital)

P10-2 Comparative study of efficacy and safety between Vonoprazan and the existing PPI for *H. pylori* eradication
Masatsugu Okuyama
(Department of Internal Medicine, Kashiwara Municipal Hospital)

P10-3 Efficacy of Vonoprazan/AMPC/CAM therapy for *H. pylori* treatment after failed eradication with PPI/AMPC/CAM
Tatsuya Toyokawa
(Department of Gastroenterology, National Hospital Organization Fukuyama Medical Center)

P10-4 A Clinical Study of The Eradication Therapy Using Vonoprazan for *Helicobacter pylori* Infection in Our Hospital.
Hideaki Matoba
(Department of Gastroenterology, Tohwa Hospital)

P10-5 Clinical outcomes of *Helicobacter pylori* eradication therapy after using Vonoprazan
Hiroki Osumi
(Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research)
### Poster Session 11
**Friday, June 24th, 2016 16:30~17:00 Poster Session (1F Convention Hall)**

**Eradication Therapy-3**

**Chair:** Taiji Akamatsu  
(Endoscopy Center, Nagano Prefectural Suzaka Hospital)

| P11-1 | **Eradication of *H. pylori* including Vonoprazan**  
Yorinari Ochiai  
(Department of Gastroenterology, Toranomon Hospital) |
|-------|---------------------------------------------------------------------------------------------------|
| P11-2 | **Results of vonoprazan fumarate -based *Helicobacter pylori* Eradication Therapy in Our Hospital**  
Youichi Saegusa  
(JCHO Sagamino Hospital) |
| P11-3 | **Recent results of eradication therapy for *Helicobacter pylori* in our institute.**  
Hitoshi Aoyagi  
(Department of Internal Medicine, Teikyo University School of Medicine) |
| P11-4 | **The results of vonoprazan based *H. pylori* eradication therapy; A study in UsaTakada medical association Hospital**  
Osamu Matsunari  
(Department of Gastroenterology, Faculty of Medicine, Oita University,  
UsaTakada Medical Association Hospital) |
| P11-5 | **Usefulness of Vonoprazan in the first, second and thired-line therapy of *H. pylori.***  
Takashi Fukuda  
(Minamiosaka Hospital,  
Osaka City University SAMURAI GI Reserch Center) |

### Poster Session 12
**Friday, June 24th, 2016 17:00~17:30 Poster Session (1F Convention Hall)**

**Eradication Therapy-4**

**Chair:** Shuichi Terao  
(Gastroenterology, Kakogawa West City Hospital)

| P12-1 | **Comparison of first and second line eradication rate for *Helicobacter pylori* between PCAB and PPI in our hospital**  
Daisuke Asaoka  
(Department of Gastroenterology, University of Juntendo, School of Medicine, Tokyo, Japan.) |
P12-2  The efficacy of Vonoprazan as *Helicobacter pylori* eradication therapy  
Yasuhiro Morita  
(Kohka public hospital)

P12-3  Current status of *Helicobacter Pylori* eradication therapy with Vonoprazan in Okayama University Hospital  
Yuka Obayashi  
(Department of Gastroenterology and Hepatology, Okayama University Graduate)

P12-4  The current state of the *Helicobacter pylori* eradication treatment by Vonoprazan in our institution.  
Mana Hosoda  
(Tokyo Womens Medical University Medical Center East)

P12-5  The usefulness of vonoprazan for *Helicobacter pylori* eradication  
Daisuke Akiyoshi  
(Fukuoka sanno Hospital)

---

**Poster Session13**  
Friday, June 24th, 2016  16:30~17:00  Poster Session (1F Convention Hall)

**Eradication Therapy- 5**

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P13-1</td>
<td>Effect of <em>Helicobacter pylori</em> eradication therapy with vonoprazan</td>
<td>Masahiko Ohtaka (Yamanashi Koseiren Health Care Center)</td>
</tr>
<tr>
<td>P13-2</td>
<td>Efficacy of <em>H.pylori</em> eradication treatments with vonoprazan including retreatments</td>
<td>Hiroshi Nagatomo (Kurihara central hospital)</td>
</tr>
<tr>
<td>P13-3</td>
<td>Availability of vonoprazan for <em>Helicobacter pylori</em> eradication</td>
<td>Junko Matsumoto (Department of Gastroenterology and Hepatology Saiseikai Suita Hospital)</td>
</tr>
<tr>
<td>P13-4</td>
<td>Efficacy and tolerability of P-CAB as first-line treatment for <em>Helicobacter pylori</em> infection</td>
<td>Sho Suzuki (Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Department of Gastroenterology, Yuri Kumiiai General Hospital)</td>
</tr>
<tr>
<td>P13-5</td>
<td>Eradication of <em>Helicobacter pylori</em> with vonoprazan</td>
<td>Hiroki Oyama (Kanto Central Hospital)</td>
</tr>
</tbody>
</table>

283
**Poster Session 14**

Friday, June 24th, 2016  17:00~17:30  Poster Session (1F Convention Hall)

**Eradication Therapy-6**

Chair: Hajime Isomoto
(2nd Department Internal Medicine, Tottori University)

**P14-1** Comparative trial of PCAB and PPI in first and second therapy for the eradication of *H. pylori*.
Kuniaki Miyazawa
(Hirosaki University, Graduate School of Medicine, Gastroenterology and Hematology)

**P14-2** Comparison of the efficacy between vonoprazan and rabeprazole in *H. pylori* eradication therapy.
Michihiro Iwaki
(Machida Municipal Hospital)

**P14-3** Safety and efficacy of *H. pylori* eradication for allergies to penicillin or after 2nd line failure of treatment.
Soichi Sugitani
(Tachikawa general hospital)

**P14-4** Current status of eradication therapy of *Helicobacter pylori* in our hospital
Akihito Tanaka
(Tanaoe hospital)

**P14-5** An increase of *Hp* eradication in the participants of X-ray mass screening in the Miyagi Cancer Society and the results.
Takashi Chiba
(Miyagi Cancer Society)

---

**Poster Session 15**

Friday, June 24th, 2016  16:30~17:00  Poster Session (1F Convention Hall)

**Eradication Therapy-7**

Chair: Kiichi Satoh
(Gastroenterology, International University of Health and Welfare Hospital)

**P15-1** Usefulness of the P-CAB-containing regimen in *H. pylori* tertiary eradication.
Shinnosuke Tokoro
(Shonan Kamakura General Hospital Gastroenterology Medicine Center)

**P15-2** Comparison of vonoprazan and esomeprazole with reference to CYP2C19 genotype
Takuma Kagami
(First Department of Medicine, Hamamatsu University School of Medicine)
P15-3  **Comparison in the eradication therapy for* H. pylori* between PPI and P-CAB**  
Hideki Okata  
(Division of Gastroenterology Tohoku university Graduate School of Medicine)

P15-4  **Comparison of esomeprazole and vonoprazan as the acid inhibitor in the first line eradication therapy for* H. pylori*.**  
Takahiro Suzuki  
(First department of medicine, Hamamatsu University of Medicine)

P15-5  **Potassium-competitive acid blocker (P-CAB) improves successful rate of* H. pylori* eradication**  
Ryo Katsumata  
(Kawasaki Medical School)

---

**Poster Session 16**  
Friday, June 24th, 2016  
17:00~17:30  Poster Session (1F Convention Hall)

**Eradication Therapy-8**

*Chair:* Seiji Futagami  
(Division of Gastroenterology, Nippon Medical School)

P16-1  **The rate of the third line eradication against *Helicobacter pylori* in our hospital**  
Mariko Hojo  
(Department of Gastroenterology, Juntendo University School of Medicine)

P16-2  **Efficacy of the third line eradication therapy including minocycline for* Helicobacter pylori* infection.**  
Toshihiko Nagaya  
(Tohno Kousei Hospital)

P16-3  **Investigation of 3rd-line therapy for* H. pylori* eradication and vonoprazan**  
Seiji Futagami  
(Division of Gastroenterology, Nippon Medical School)

P16-4  **A recent one-year trends of *Helicobacter pylori* eradication in our hospital**  
Akihiko Tsuchiya  
(Ageo Central General Hospital)

P16-5  **A case report of* Helicobacter pylori* eradication with vonoprazan after third line treatment.**  
Yuya Yamashiro  
(Ageo Central General Hospital)
**Poster Session 17**

Friday, June 24th, 2016  16:30~17:00  Poster Session (1F Convention Hall)

**Eradication therapy 9**

Chair: Nobuhiro Sakaki  
(Foundation for Detection of Early Gastric Carcinoma)

P17-1 **Vonoprazan-based eradication therapy for *H. pylori* infection**  
Sanae Tanaka  
(Kobe Red Cross Hospital)

P17-2 **Usefulness of eradication therapy to *H. pylori* using vonoprazan, considering the sensitivity to clarithromycin**  
Hiroyuki Nishibayashi  
(Department of Gastroenterology and Hepatology, Kawanishi Municipal Hospital)

P17-3 **Comparison of *Helicobacter pylori* eradication therapy using P-CAB and rabeprazole in our region.**  
Atsushi Okuyama  
(Department of Gastroenterology, Yokote Municipal Hospital)

P17-4 **Treatment outcome of vonoprazan-based triple *H. pylori* eradication therapy**  
Taketo Otsuka  
(Division of Gastroenterology, Shiga university of medical science)

P17-5 **Retrospective analysis of usefulness of Vonoplazan in first-line therapy for *Helicobacter pylori* infection.**  
Ryo Kondo  
(Tokyo Metropolitan Police Hospital)

---

**Poster Session 18**

Friday, June 24th, 2016  17:00~17:30  Poster Session (1F Convention Hall)

**Eradication therapy 10**

Chair: Yuji Mizokami  
(Endoscopic Center, University of Tsukuba Hospital)

P18-1 **The study of risk factors for reflux esophagitis after *H. pylori* eradication therapy**  
Akira Harada  
(Matsuyama Red Cross Hospital  Department of Gastroentology)

P18-2 **The actual situation in *Helicobacter pylori* eradication therapies for elder patients of seventy five years and up.**  
Hitoshi Sasaki  
(Juntendo Tokyo Koto Geriatric Medical Center)
**P18-3**  Antibiotic-associated hemorrhagic colitis after eradication therapy for *Helicobacter pylori*
Keisuke Toguchi
(mimihara general hospital department of surgery)

**P18-4**  *Helicobacter pylori* eradication therapy for remnant stomach
Akihito Kamuro
(Joetsu general hospital)

**P18-5**  Efficacy of the third line eradication rate of *H. pylori* using metronidazole and minocycline or sitafloxacin
Takahiro Horii
(Horii Clinic)

---

**Poster Session 19**
Friday, June 24th, 2016  16:30~17:00  Poster Session (1F  Convention Hall)

### Antibiotics Resistance

Chair: Akihito Nagahara
(Gastroenterology, Juntendo University Shizuoka Hospital)

**P19-1**  Antibiotic resistance rate of *Helicobacter pylori* clinical isolates in Okayama University hospital
Masahide Kita
(Department of Gastroenterology, Okayama University Hospital,
Department of Gastroenterology, Okayama City Okayama Citizens Hospital)

**P19-2**  Usefulness of five antibiotics susceptibility test for *Helicobacter pylori* eradication
Tsuneo Araki
(Araki clinic)

**P19-3**  Safety and efficacy of sitafloxacin-based third-line eradication therapy for *Helicobacter pylori*
Ryoya Seki
(Department of Gastroenterology, Japanese Red Cross Date General Hospital)

**P19-4**  Analysis of *Helicobacter pylori* genotypes in clinical gastric wash samples
Yoshiyuki Watanabe
(Kawasaki Rinko General Hospital, Department of Internal Medicine,
St. Marianna University School of Medicine, Division of Gastroenterology and Hepatology)

**P19-5**  Potent Anti-*Helicobacter pylori* Activity of Medicinal Plants from the Kingdom of Saudi Arabia
Jibran Sualeh Muhammad
(Department of Gastroenterology, Faculty of Medicine, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Japan)
English presentation

Chair: Yoshio Yamaoka
(Department of Environmental and Preventive Medicine, Oita University, Department of Medicine-Gastroenterology, Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center)

P20-1 Epidermiology, diagnosis and management of *H. pylori* infection in Vietnamese children
Thi Viet Ha Nguyen
(Department of Pediatric, Hanoi Medical University
Gastroenterology Department, National Hospital of Pediatrics)

P20-2 Randomized clinical trial: Comparison of a 10 day sequential, bismuth – Containing quadruple therapies with standard triple therapy for *Helicobacter pylori* eradication
Bira Namdag
(Gastroenterology and Hepatology Unit, Department of Internal Medicine II, School of Medicine, Mongolian National University of Medical Sciences)